CR-1-31-B
Based on 12 publication(s) in Google Scholar
CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.38%
- CAS No.: 1352914-52-3
- 화학식: C28H29NO8
- 분자량:507.53
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CR-1-31-B
More- Adv Sci (Weinh). 2025 Sep 4:e06925. [Abstract]
- J Exp Clin Cancer Res. 2022 Dec 9;41(1):340. [Abstract]
- Clin Cancer Res. 2024 Oct 1;30(19):4464-4481. [Abstract]
- Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2321305121. [Abstract]
- Cell Rep. 2026 Jun 23;45(6):117520. [Abstract]
- Cell Rep. 2024 Dec 24;43(12):114945. [Abstract]
- Int J Mol Sci. 2023 Jan 20;24(3):2055. [Abstract]
- iScience. 2023 Nov 19;26(12):108492. [Abstract]
- bioRxiv. 2025 Nov 18.
- University of Cincinnati. 2025.
- Université de Montréal. 2023 Aug.
- Research Square Preprint. 2022 Jun.
Biological Activity
|
eIF4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BJAB | IC50 |
0.5 nM
Compound: (-)-9, JAP-CR-1-31-B
|
Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 72 hr by scintillation counting
Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 72 hr by scintillation counting
|
[PMID: 22128783] |
| BJAB | IC50 |
1.5 nM
Compound: (-)-9, JAP-CR-1-31-B
|
Cytotoxicity against human BJAB cells after 72 hrs by PI-staining based flow cytometric analysis
Cytotoxicity against human BJAB cells after 72 hrs by PI-staining based flow cytometric analysis
|
[PMID: 22128783] |
| BJAB | IC50 |
20 nM
Compound: (-)-9, JAP-CR-1-31-B
|
Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 1 hr by scintillation counting
Inhibition of eIF4A1-mediated protein synthesis in human BJAB cells assessed as inhibition of [35S]Met incorporation after 1 hr by scintillation counting
|
[PMID: 22128783] |
| HepG2 | CC50 |
14.3 nM
Compound: rac-1c; (+/-)-CR-31-B
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 38127656] |
| HepG2 | CC50 |
188.3 nM
Compound: rac-1c; (+/-)-CR-31-B
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 38127656] |
| NIH3T3 | IC50 |
9 nM
Compound: 9; CR-1-31-B
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 4 days by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 4 days by SRB assay
|
[PMID: 33592144] |
CR-1-31-B (100 nM; 24 hours) inhibits MUC1-C translation in MCF-10A cells (EGF-stimulated)[1].
CR-1-31-B (10 and 100 nM) decreases MUC1-C abundance in MDA-MB-468 breast cancer cells[1].
CR-1-31B sensitizes gallbladder cancer cells to TRAIL-mediated apoptosis through the translational downregulation of c-FLIP[2].
Neuroblastoma (NB) cell lines exhibit decreased viability, increased apoptosis rates as well as changes in cell cycle distribution when treated with the synthetic rocaglate CR-1-31-B (24-72 hours), which clamps eIF4A and eIF4F onto mRNA, resulting in a translational block[4].
CR-1-31-B (100 nM; 5 hours) treatment increases reverse glutamine metabolism in pancreatic cancer cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-10A cells (EGF-stimulated)
-
Concentration:100 nM
-
Incubation Time:24 hours
-
Result:Blocked increases in MUC1-C abundance.
-
Cell Line:SH-SY5Y cells and Kelly cells
-
Concentration:0.1-100 nM
-
Incubation Time:24-72 hours
-
Result:A significant decrease in SH-SY5Y viability was observed at 10 nM for all time points. Significantly decreased the viability of Kelly cells at 5 nM. The calculated IC50 at 48 h was 20 nM for SH-SY5Y and 4 nM for Kelly cells.
-
Cell Line:SH-SY5Y and Kelly cells
-
Concentration:SH-SY5Y cells were treated with 10, 20, and 50 nM and Kelly cells with 1, 5, and 10 nM
-
Incubation Time:24-72 hours
-
Result:Triggered apoptosis.
CR-1-31-B (0.2 mg/kg; IP; daily for 7 days; murine orthotopic transplant model of pancreatic ductal adenocarcinoma) effectively inhibits protein synthesis and growth of pancreatic tumours[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1352914-52-3
-
Appearance Solid
-
분자량 507.53
-
화학식 C28H29NO8
-
Color White to off-white
-
SMILES
O=C([C@H]([C@H]1C2=CC=CC=C2)[C@@H](O)[C@]3(O)[C@@]1(C4=CC=C(OC)C=C4)OC5=CC(OC)=CC(OC)=C35)NOC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Spatial Transcriptomics Reveals Transcriptomic and Immune Microenvironment Reprogramming during Thyroid Carcinoma Dedifferentiation. [Abstract]2025 Sep 4:e06925. PMID: 40908584 -
J Exp Clin Cancer Res
EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax. [Abstract]2022 Dec 9;41(1):340. PMID: 36482393 -
Clin Cancer Res
Pharmacologic inhibition of eIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. [Abstract]2024 Oct 1;30(19):4464-4481. PMID: 39078310 -
Proc Natl Acad Sci U S A
2024 Oct 29;121(44):e2321305121. PMID: 39436655 -
Cell Rep
Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer. [Abstract]2026 Jun 23;45(6):117520. PMID: 42284146 -
Cell Rep
PPARγ-dependent remodeling of translational machinery in adipose progenitors is impaired in obesity. [Abstract]2024 Dec 24;43(12):114945. PMID: 39579770 -
Int J Mol Sci
2023 Jan 20;24(3):2055. PMID: 36768380 -
iScience
Programmable modulation of ribosomal frameshifting by mRNA targeting CRISPR-Cas12a system. [Abstract]2023 Nov 19;26(12):108492. PMID: 38125012 -
-
-
-
용액&용해도
DMSO : 230 mg/mL (453.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5.75 mg/mL (11.33 mM); Clear solution
This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5.75 mg/mL (11.33 mM); Clear solution
This protocol yields a clear solution of ≥ 5.75 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (57.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (288 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jin C, Rajabi H, Rodrigo CM, Porco JA Jr, Kufe D. Targeting the eIF4A RNA helicase blocks translation of the MUC1-C oncoprotein. Oncogene. 2013;32(17):2179-2188. [Content Brief]
[2]. Cao Y, et al. Targeting eIF4A using rocaglate CR 1 31B sensitizes gallbladder cancer cells to TRAIL mediated apoptosis through the translational downregulation of c FLIP. Oncol Rep. 2021;45(1):230-238. [Content Brief]
[3]. Langlais D, et al. Rocaglates as dual-targeting agents for experimental cerebral malaria. Proc Natl Acad Sci U S A. 2018;115(10):E2366-E2375. [Content Brief]
[4]. Skofler C, et al. Eukaryotic Translation Initiation Factor 4AI: A Potential Novel Target in Neuroblastoma. Cells. 2021;10(2):301. Published 2021 Feb 2. [Content Brief]
[5]. Chan K, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nat Commun. 2019;10(1):5151. Published 2019 Nov 13. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9703 mL | 9.8516 mL | 19.7033 mL | 49.2582 mL |
| 5 mM | 0.3941 mL | 1.9703 mL | 3.9407 mL | 9.8516 mL | |
| 10 mM | 0.1970 mL | 0.9852 mL | 1.9703 mL | 4.9258 mL | |
| 15 mM | 0.1314 mL | 0.6568 mL | 1.3136 mL | 3.2839 mL | |
| 20 mM | 0.0985 mL | 0.4926 mL | 0.9852 mL | 2.4629 mL | |
| 25 mM | 0.0788 mL | 0.3941 mL | 0.7881 mL | 1.9703 mL | |
| 30 mM | 0.0657 mL | 0.3284 mL | 0.6568 mL | 1.6419 mL | |
| 40 mM | 0.0493 mL | 0.2463 mL | 0.4926 mL | 1.2315 mL | |
| 50 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL | 0.9852 mL | |
| 60 mM | 0.0328 mL | 0.1642 mL | 0.3284 mL | 0.8210 mL | |
| 80 mM | 0.0246 mL | 0.1231 mL | 0.2463 mL | 0.6157 mL | |
| 100 mM | 0.0197 mL | 0.0985 mL | 0.1970 mL | 0.4926 mL |
Powered by Bioz